Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Principles of Pharmacogenetics: Types of Genetic Variants

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Batch-dependent safety signal: Nationwide analysis of suspected adverse events following COVID-19 vaccination in Germany.

The International journal of risk & safety in medicine·2026

Same author

Balloon Lithotripsy Added to Conventional Preparation Before Stent Implantation in Severely Calcified Coronary Lesions.

JACC. Cardiovascular interventions·2025

Same author

The association between self-reported frailty status and 1-year all-cause mortality and readmission following PCI: A prospective multi-centre cohort study, CONCARD<sup>PCI</sup>.

International journal of cardiology·2025

Same author

High-sensitivity C-reactive protein is associated with altered cardiac structure and function in psoriasis: The PSOCADIA study.

International journal of cardiology. Heart & vasculature·2025

Same author

Safety of BNT162b2 mRNA COVID-19 Vaccine Batches: A Nationwide Cohort Study.

Pharmacoepidemiology and drug safety·2025

Same author

Antibodies to Periodontal Bacteria Are Associated with Systemic Lupus Erythematosus and Autoantibody Positivity.

International journal of molecular sciences·2025

Search research articles

Related Experiment Video

Updated: Jun 23, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

[Cardiovascular pharmacogenomics].

Ole Ahlehoff¹, Peter Riis Hansen

¹Gentofte Hospital, DK-2900 Hellerup.

Ugeskrift for Laeger

|May 6, 2009

Summary

This summary is machine-generated.

Advances in cardiovascular pharmacogenomics show genetic information can personalize treatment with betablockers, statins, and warfarin. Personalized cardiovascular pharmacotherapy is nearing clinical practice, pending randomized trials.

More Related Videos

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Published on: September 13, 2022

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Related Experiment Videos

Last Updated: Jun 23, 2026

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Intradermal Microdialysis: An Approach to Investigating Novel Mechanisms of Microvascular Dysfunction in Humans

Published on: July 21, 2023

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Dynamic Continuous Blood Extraction from Rat Heart via Noninvasive Microdialysis Technique

Published on: September 13, 2022

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Exercise Test for Evaluation of the Functional Efficacy of the Pig Cardiovascular System

Published on: May 12, 2023

Area of Science:

Genomics and Precision Medicine
Cardiovascular Pharmacology
Biotechnology

Context:

Recent genome-wide surveys have significantly advanced cardiovascular pharmacogenomics.
Genetic information is increasingly recognized for its role in optimizing drug therapy.
Current treatment paradigms are evolving with personalized approaches.

Purpose:

To review recent advances in cardiovascular pharmacogenomics.
To highlight the value of genetic information in tailoring drug treatments.
To discuss the potential of personalized pharmacotherapy in cardiovascular disease.

Summary:

The field of cardiovascular pharmacogenomics has seen substantial progress, driven by genome-wide association studies.
Genetic profiling aids in the personalized treatment of cardiovascular diseases using drugs like betablockers, statins, and warfarin.
While definitive outcome data from randomized trials are pending, personalized cardiovascular pharmacotherapy is poised for clinical integration.

Impact:

This review underscores the transformative potential of genetic insights in cardiovascular medicine.
Personalized pharmacotherapy promises to improve patient outcomes and treatment efficacy.
The findings pave the way for a new era of precision medicine in cardiovascular care.